Global Wet Age Related Macular Degeneration (AMD) Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Page: 111
Published Date: 02 Jan 2024
Category: Medical Care
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Wet Age Related Macular Degeneration (AMD) market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.
The Global Info Research report includes an overview of the development of the Wet Age Related Macular Degeneration (AMD) industry chain, the market status of Above 75 Years (Wet Age-Related Macular Degeneration (Wet AMD), Dry Age-Related Macular Degeneration (Dry AMD)), Above 60 Years (Wet Age-Related Macular Degeneration (Wet AMD), Dry Age-Related Macular Degeneration (Dry AMD)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Wet Age Related Macular Degeneration (AMD).
Regionally, the report analyzes the Wet Age Related Macular Degeneration (AMD) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Wet Age Related Macular Degeneration (AMD) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Wet Age Related Macular Degeneration (AMD) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Wet Age Related Macular Degeneration (AMD) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Wet Age-Related Macular Degeneration (Wet AMD), Dry Age-Related Macular Degeneration (Dry AMD)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Wet Age Related Macular Degeneration (AMD) market.
Regional Analysis: The report involves examining the Wet Age Related Macular Degeneration (AMD) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Wet Age Related Macular Degeneration (AMD) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Wet Age Related Macular Degeneration (AMD):
Company Analysis: Report covers individual Wet Age Related Macular Degeneration (AMD) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Wet Age Related Macular Degeneration (AMD) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Age (Above 75 Years, Above 60 Years).
Technology Analysis: Report covers specific technologies relevant to Wet Age Related Macular Degeneration (AMD). It assesses the current state, advancements, and potential future developments in Wet Age Related Macular Degeneration (AMD) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Wet Age Related Macular Degeneration (AMD) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Wet Age Related Macular Degeneration (AMD) market is split by Type and by Age. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Age in terms of value.
Market segment by Type
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)
Market segment by Age
Above 75 Years
Above 60 Years
Above 40 Years
Market segment by players, this report covers
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Wet Age Related Macular Degeneration (AMD) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Wet Age Related Macular Degeneration (AMD), with revenue, gross margin and global market share of Wet Age Related Macular Degeneration (AMD) from 2019 to 2024.
Chapter 3, the Wet Age Related Macular Degeneration (AMD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Wet Age Related Macular Degeneration (AMD) market forecast, by regions, type and age, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Wet Age Related Macular Degeneration (AMD).
Chapter 13, to describe Wet Age Related Macular Degeneration (AMD) research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Wet Age Related Macular Degeneration (AMD)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Wet Age Related Macular Degeneration (AMD) by Type
1.3.1 Overview: Global Wet Age Related Macular Degeneration (AMD) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type in 2023
1.3.3 Wet Age-Related Macular Degeneration (Wet AMD)
1.3.4 Dry Age-Related Macular Degeneration (Dry AMD)
1.4 Global Wet Age Related Macular Degeneration (AMD) Market by Age
1.4.1 Overview: Global Wet Age Related Macular Degeneration (AMD) Market Size by Age: 2019 Versus 2023 Versus 2030
1.4.2 Above 75 Years
1.4.3 Above 60 Years
1.4.4 Above 40 Years
1.5 Global Wet Age Related Macular Degeneration (AMD) Market Size & Forecast
1.6 Global Wet Age Related Macular Degeneration (AMD) Market Size and Forecast by Region
1.6.1 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Wet Age Related Macular Degeneration (AMD) Market Size by Region, (2019-2030)
1.6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2019-2030)
1.6.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2019-2030)
1.6.6 South America Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Wet Age Related Macular Degeneration (AMD) Market Size and Prospect (2019-2030)
2.1 Novartis International (Switzerland)
2.1.1 Novartis International (Switzerland) Details
2.1.2 Novartis International (Switzerland) Major Business
2.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.1.4 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novartis International (Switzerland) Recent Developments and Future Plans
2.2 Bayer (Germany)
2.2.1 Bayer (Germany) Details
2.2.2 Bayer (Germany) Major Business
2.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.2.4 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bayer (Germany) Recent Developments and Future Plans
2.3 Acucela (US)
2.3.1 Acucela (US) Details
2.3.2 Acucela (US) Major Business
2.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.3.4 Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Acucela (US) Recent Developments and Future Plans
2.4 Neurotech Pharmaceuticals (US)
2.4.1 Neurotech Pharmaceuticals (US) Details
2.4.2 Neurotech Pharmaceuticals (US) Major Business
2.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.4.4 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Neurotech Pharmaceuticals (US) Recent Developments and Future Plans
2.5 Ophthotech (US)
2.5.1 Ophthotech (US) Details
2.5.2 Ophthotech (US) Major Business
2.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.5.4 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Ophthotech (US) Recent Developments and Future Plans
2.6 GlaxoSmithKline (US)
2.6.1 GlaxoSmithKline (US) Details
2.6.2 GlaxoSmithKline (US) Major Business
2.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.6.4 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 GlaxoSmithKline (US) Recent Developments and Future Plans
2.7 Alimera Sciences (US)
2.7.1 Alimera Sciences (US) Details
2.7.2 Alimera Sciences (US) Major Business
2.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.7.4 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Alimera Sciences (US) Recent Developments and Future Plans
2.8 StemCell (Canada)
2.8.1 StemCell (Canada) Details
2.8.2 StemCell (Canada) Major Business
2.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.8.4 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 StemCell (Canada) Recent Developments and Future Plans
2.9 F. Hoffmann-La Roche (Switzerland)
2.9.1 F. Hoffmann-La Roche (Switzerland) Details
2.9.2 F. Hoffmann-La Roche (Switzerland) Major Business
2.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.9.4 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 F. Hoffmann-La Roche (Switzerland) Recent Developments and Future Plans
2.10 Regeneron Pharmaceutical (US)
2.10.1 Regeneron Pharmaceutical (US) Details
2.10.2 Regeneron Pharmaceutical (US) Major Business
2.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.10.4 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Regeneron Pharmaceutical (US) Recent Developments and Future Plans
2.11 Allergan (Ireland)
2.11.1 Allergan (Ireland) Details
2.11.2 Allergan (Ireland) Major Business
2.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.11.4 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Allergan (Ireland) Recent Developments and Future Plans
2.12 Adverum Biotechnologies (US)
2.12.1 Adverum Biotechnologies (US) Details
2.12.2 Adverum Biotechnologies (US) Major Business
2.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.12.4 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Adverum Biotechnologies (US) Recent Developments and Future Plans
2.13 Gilead Sciences (US)
2.13.1 Gilead Sciences (US) Details
2.13.2 Gilead Sciences (US) Major Business
2.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
2.13.4 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Gilead Sciences (US) Recent Developments and Future Plans
3.1 Global Wet Age Related Macular Degeneration (AMD) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Wet Age Related Macular Degeneration (AMD) by Company Revenue
3.2.2 Top 3 Wet Age Related Macular Degeneration (AMD) Players Market Share in 2023
3.2.3 Top 6 Wet Age Related Macular Degeneration (AMD) Players Market Share in 2023
3.3 Wet Age Related Macular Degeneration (AMD) Market: Overall Company Footprint Analysis
3.3.1 Wet Age Related Macular Degeneration (AMD) Market: Region Footprint
3.3.2 Wet Age Related Macular Degeneration (AMD) Market: Company Product Type Footprint
3.3.3 Wet Age Related Macular Degeneration (AMD) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Wet Age Related Macular Degeneration (AMD) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Type (2025-2030)
5.1 Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2019-2024)
5.2 Global Wet Age Related Macular Degeneration (AMD) Market Forecast by Age (2025-2030)
6.1 North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2030)
6.2 North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2030)
6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country
6.3.1 North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2030)
6.3.2 United States Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
6.3.3 Canada Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
6.3.4 Mexico Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
7.1 Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2030)
7.2 Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2030)
7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country
7.3.1 Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2030)
7.3.2 Germany Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
7.3.3 France Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
7.3.5 Russia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
7.3.6 Italy Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
8.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2030)
8.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region
8.3.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2019-2030)
8.3.2 China Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
8.3.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
8.3.4 South Korea Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
8.3.5 India Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
8.3.7 Australia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
9.1 South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2030)
9.2 South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2030)
9.3 South America Wet Age Related Macular Degeneration (AMD) Market Size by Country
9.3.1 South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2030)
9.3.2 Brazil Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
9.3.3 Argentina Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
10.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2030)
10.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country
10.3.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2030)
10.3.2 Turkey Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
10.3.4 UAE Wet Age Related Macular Degeneration (AMD) Market Size and Forecast (2019-2030)
11.1 Wet Age Related Macular Degeneration (AMD) Market Drivers
11.2 Wet Age Related Macular Degeneration (AMD) Market Restraints
11.3 Wet Age Related Macular Degeneration (AMD) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12.1 Wet Age Related Macular Degeneration (AMD) Industry Chain
12.2 Wet Age Related Macular Degeneration (AMD) Upstream Analysis
12.3 Wet Age Related Macular Degeneration (AMD) Midstream Analysis
12.4 Wet Age Related Macular Degeneration (AMD) Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Age, (USD Million), 2019 & 2023 & 2030
Table 3. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Novartis International (Switzerland) Company Information, Head Office, and Major Competitors
Table 6. Novartis International (Switzerland) Major Business
Table 7. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 8. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Novartis International (Switzerland) Recent Developments and Future Plans
Table 10. Bayer (Germany) Company Information, Head Office, and Major Competitors
Table 11. Bayer (Germany) Major Business
Table 12. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 13. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Bayer (Germany) Recent Developments and Future Plans
Table 15. Acucela (US) Company Information, Head Office, and Major Competitors
Table 16. Acucela (US) Major Business
Table 17. Acucela (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 18. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Acucela (US) Recent Developments and Future Plans
Table 20. Neurotech Pharmaceuticals (US) Company Information, Head Office, and Major Competitors
Table 21. Neurotech Pharmaceuticals (US) Major Business
Table 22. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 23. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Neurotech Pharmaceuticals (US) Recent Developments and Future Plans
Table 25. Ophthotech (US) Company Information, Head Office, and Major Competitors
Table 26. Ophthotech (US) Major Business
Table 27. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 28. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Ophthotech (US) Recent Developments and Future Plans
Table 30. GlaxoSmithKline (US) Company Information, Head Office, and Major Competitors
Table 31. GlaxoSmithKline (US) Major Business
Table 32. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 33. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. GlaxoSmithKline (US) Recent Developments and Future Plans
Table 35. Alimera Sciences (US) Company Information, Head Office, and Major Competitors
Table 36. Alimera Sciences (US) Major Business
Table 37. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 38. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Alimera Sciences (US) Recent Developments and Future Plans
Table 40. StemCell (Canada) Company Information, Head Office, and Major Competitors
Table 41. StemCell (Canada) Major Business
Table 42. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 43. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. StemCell (Canada) Recent Developments and Future Plans
Table 45. F. Hoffmann-La Roche (Switzerland) Company Information, Head Office, and Major Competitors
Table 46. F. Hoffmann-La Roche (Switzerland) Major Business
Table 47. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 48. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. F. Hoffmann-La Roche (Switzerland) Recent Developments and Future Plans
Table 50. Regeneron Pharmaceutical (US) Company Information, Head Office, and Major Competitors
Table 51. Regeneron Pharmaceutical (US) Major Business
Table 52. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 53. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Regeneron Pharmaceutical (US) Recent Developments and Future Plans
Table 55. Allergan (Ireland) Company Information, Head Office, and Major Competitors
Table 56. Allergan (Ireland) Major Business
Table 57. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 58. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Allergan (Ireland) Recent Developments and Future Plans
Table 60. Adverum Biotechnologies (US) Company Information, Head Office, and Major Competitors
Table 61. Adverum Biotechnologies (US) Major Business
Table 62. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 63. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Adverum Biotechnologies (US) Recent Developments and Future Plans
Table 65. Gilead Sciences (US) Company Information, Head Office, and Major Competitors
Table 66. Gilead Sciences (US) Major Business
Table 67. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product and Solutions
Table 68. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. Gilead Sciences (US) Recent Developments and Future Plans
Table 70. Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Million) by Players (2019-2024)
Table 71. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Players (2019-2024)
Table 72. Breakdown of Wet Age Related Macular Degeneration (AMD) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 73. Market Position of Players in Wet Age Related Macular Degeneration (AMD), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 74. Head Office of Key Wet Age Related Macular Degeneration (AMD) Players
Table 75. Wet Age Related Macular Degeneration (AMD) Market: Company Product Type Footprint
Table 76. Wet Age Related Macular Degeneration (AMD) Market: Company Product Application Footprint
Table 77. Wet Age Related Macular Degeneration (AMD) New Market Entrants and Barriers to Market Entry
Table 78. Wet Age Related Macular Degeneration (AMD) Mergers, Acquisition, Agreements, and Collaborations
Table 79. Global Wet Age Related Macular Degeneration (AMD) Consumption Value (USD Million) by Type (2019-2024)
Table 80. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Share by Type (2019-2024)
Table 81. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Forecast by Type (2025-2030)
Table 82. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2024)
Table 83. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Forecast by Age (2025-2030)
Table 84. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2024) & (USD Million)
Table 85. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2025-2030) & (USD Million)
Table 86. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2024) & (USD Million)
Table 87. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2025-2030) & (USD Million)
Table 88. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2024) & (USD Million)
Table 89. North America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2025-2030) & (USD Million)
Table 90. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2024) & (USD Million)
Table 91. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2025-2030) & (USD Million)
Table 92. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2024) & (USD Million)
Table 93. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2025-2030) & (USD Million)
Table 94. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2024) & (USD Million)
Table 95. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2025-2030) & (USD Million)
Table 96. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2024) & (USD Million)
Table 97. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2025-2030) & (USD Million)
Table 98. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2024) & (USD Million)
Table 99. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2025-2030) & (USD Million)
Table 100. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2019-2024) & (USD Million)
Table 101. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value by Region (2025-2030) & (USD Million)
Table 102. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2024) & (USD Million)
Table 103. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2025-2030) & (USD Million)
Table 104. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2024) & (USD Million)
Table 105. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2025-2030) & (USD Million)
Table 106. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2024) & (USD Million)
Table 107. South America Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2025-2030) & (USD Million)
Table 108. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2019-2024) & (USD Million)
Table 109. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Type (2025-2030) & (USD Million)
Table 110. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2019-2024) & (USD Million)
Table 111. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Age (2025-2030) & (USD Million)
Table 112. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2019-2024) & (USD Million)
Table 113. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Consumption Value by Country (2025-2030) & (USD Million)
Table 114. Wet Age Related Macular Degeneration (AMD) Raw Material
Table 115. Key Suppliers of Wet Age Related Macular Degeneration (AMD) Raw Materials
List of Figures
Figure 1. Wet Age Related Macular Degeneration (AMD) Picture
Figure 2. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type in 2023
Figure 4. Wet Age-Related Macular Degeneration (Wet AMD)
Figure 5. Dry Age-Related Macular Degeneration (Dry AMD)
Figure 6. Global Wet Age Related Macular Degeneration (AMD) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age in 2023
Figure 8. Above 75 Years Picture
Figure 9. Above 60 Years Picture
Figure 10. Above 40 Years Picture
Figure 11. Global Wet Age Related Macular Degeneration (AMD) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Wet Age Related Macular Degeneration (AMD) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Market Wet Age Related Macular Degeneration (AMD) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 14. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Region (2019-2030)
Figure 15. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Region in 2023
Figure 16. North America Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 17. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 18. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 19. South America Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 20. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 21. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Players in 2023
Figure 22. Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 23. Global Top 3 Players Wet Age Related Macular Degeneration (AMD) Market Share in 2023
Figure 24. Global Top 6 Players Wet Age Related Macular Degeneration (AMD) Market Share in 2023
Figure 25. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Share by Type (2019-2024)
Figure 26. Global Wet Age Related Macular Degeneration (AMD) Market Share Forecast by Type (2025-2030)
Figure 27. Global Wet Age Related Macular Degeneration (AMD) Consumption Value Share by Age (2019-2024)
Figure 28. Global Wet Age Related Macular Degeneration (AMD) Market Share Forecast by Age (2025-2030)
Figure 29. North America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2019-2030)
Figure 30. North America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2019-2030)
Figure 31. North America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2019-2030)
Figure 32. United States Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 33. Canada Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 34. Mexico Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 35. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2019-2030)
Figure 36. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2019-2030)
Figure 37. Europe Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2019-2030)
Figure 38. Germany Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 39. France Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 40. United Kingdom Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 41. Russia Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 42. Italy Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 43. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2019-2030)
Figure 44. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2019-2030)
Figure 45. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Region (2019-2030)
Figure 46. China Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 47. Japan Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 48. South Korea Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 49. India Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 50. Southeast Asia Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 51. Australia Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 52. South America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2019-2030)
Figure 53. South America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2019-2030)
Figure 54. South America Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2019-2030)
Figure 55. Brazil Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 56. Argentina Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 57. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Type (2019-2030)
Figure 58. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Age (2019-2030)
Figure 59. Middle East and Africa Wet Age Related Macular Degeneration (AMD) Consumption Value Market Share by Country (2019-2030)
Figure 60. Turkey Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 61. Saudi Arabia Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 62. UAE Wet Age Related Macular Degeneration (AMD) Consumption Value (2019-2030) & (USD Million)
Figure 63. Wet Age Related Macular Degeneration (AMD) Market Drivers
Figure 64. Wet Age Related Macular Degeneration (AMD) Market Restraints
Figure 65. Wet Age Related Macular Degeneration (AMD) Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Wet Age Related Macular Degeneration (AMD) in 2023
Figure 68. Manufacturing Process Analysis of Wet Age Related Macular Degeneration (AMD)
Figure 69. Wet Age Related Macular Degeneration (AMD) Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Novartis International (Switzerland) Bayer (Germany) Acucela (US) Neurotech Pharmaceuticals (US) Ophthotech (US) GlaxoSmithKline (US) Alimera Sciences (US) StemCell (Canada) F. Hoffmann-La Roche (Switzerland) Regeneron Pharmaceutical (US) Allergan (Ireland) Adverum Biotechnologies (US) Gilead Sciences (US)
Related Reports
07 Jan 2023
Medical Care
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
